secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001140361-22-040700
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics Q3 revenue $41.1M (+99% YoY); raises FY2022 guidance to $145M
----------------------------------------------------------------------------

- Q3 revenue $41.1M (+99% YoY from $20.7M); gross profit $9.7M vs $0.4M; net loss $14.9M ($0.08 loss/share) narrowing from $17.7M.
- FY2022 revenue guidance raised to ~$145M from prior $130M; reiterates profitability target no later than Q1 2024.
- ASCENIV record pull-through; ongoing strategic review with Morgan Stanley; BioCenters on track for 10 FDA-licensed centers by 2023.
- Long-term targets: revenue $250M+ in 2024, $300M+ thereafter; gross margins 40-50%, net income margins 20-30%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036122040700/0001140361-22-040700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036122040700/brhc10043955_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-040700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer